Cardiovascular risk markers in hemodialysis patients

International Journal of Artificial Organs

Volumn 27, Issue 12, 2004, Pages 1083-1090

  Urso, S ^a   Garozzo, M ^a   Milone, F ^a   Battaglia, G ^a  

^a Ospedale S Marta e S Venera   (Italy)

Author keywords

CK MB mass; ESRD; HDF on line; Hemodialysis; Homocysteine; Troponin I

Indexed keywords

BODY FLUIDS; CHLORINE; HEMODIALYZERS; POTASSIUM;

CARDIOVASCULAR RISK; CK-MB MASS; ESRD; HAEMODIALYSIS; HDF ON-LINE; HEMODIALYSIS PATIENT; HOMOCYSTEINES; TROPONIN; TROPONIN I; UREMIC PATIENTS;

DIALYSIS;

BICARBONATE; BIOLOGICAL MARKER; ELECTROLYTE; FOLIC ACID; POTASSIUM; SODIUM; TROPONIN T;

ACUTE DISEASE; ACUTE HEART INFARCTION; ADULT; AGED; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MALE; MORTALITY; PATIENT SELECTION; PH; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SODIUM BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; UREMIA;

EID: 12444303333     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880402701212     Document Type: Article

References (39)

1. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142-6.
2. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-14.
3. Herzog C, Ma J, Collins A. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
4. Collins P. Measurement of cardiac troponins. Ann Clin Biochem 2001; 38: 423-49.
5. Goldmann BU, Christenson RH, Hamm CW, Meinertz T, Ohman EM. Implications of troponin testing in clinical medicine. Curr Control Trials Cardiovasc Med 2001; 2: 75-84.
6. Iliou M, Fumeron C, Benoit MO, et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis and new cardiac markers evaluation (CHANCE) study. Nephrol Dial Transplant 2001; 16: 1452-8.
7. Gürbilek M. Cardiac Troponin-I before and after renal dialysis. (Letter) Clin Nephrol 2000; 54.
8. Lipshultz SE, Somers MJ, Lipsitz SR, Colan SD, Jabs K, Rifai N. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 2003; 112: 79-86.
9. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-5.
10. Iliou M, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: chronic hemodialysis and new cardiac markers evaluation (CHANCE) study. Am J Kidney Dis 2003; 42: 513-23.
11. Timio M, Saronio P, Verdura C, Venanzi S, Timio F. Fattori patogenetici emergenti e prevenzione della cardiovasculopatia aterosclerotica nell'uremia. G Ital Nefrol 2003; 20 (suppl 22): S17-21.
12. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
13. Martin G, Becker B, Schulman G. Cardiac troponin I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant 1998; 13: 1709-12.
14. Solaro R. Troponin I, stunning hypertrophy, and failure of the heart. Circ Res 1999; 84: 122-4.
15. George S, Singh A. Current markers of myocardial ischemia and their validity in end-stage renal disease. Curr Opin Nephrol Hypertens 1999; 8: 719-22.
16. Willings S, Keller F, Steinbach G. Specificity of cardiac Troponin I and T in renal disease. Clin Chem Lab Med 1998; 36: 87.
17. Perry SV. The regulation of contractile activity in muscle. Biochem Soc Trans 1979; 7: 593.
18. Wilkinson JM, Grand RJ. Comparison of amino acid sequence of troponin I from different striated muscles. Nature 1978; 271: 31.
19. Larue C, Calzolari C, Bertinchant JP, et al. Cardiac-specific enzymometric assays of troponin-I in early phase of acute myocardial infarction. Clin Chem 1993; 39: 972.
20. Boston AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease. Prevalence, etiology and potential relationship to arteriosclerotic outcome. Kidney Int 1997; 52: 10-20.
21. Brattrstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 2000; 72: 315-23.
22. Suliman ME, Stenvinkel P, Heimburger O, et al. Plasma sulphur amino acids in relation to cardiovascular disease, nutritional status and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 2002; 40; 480-8.
23. Suliman ME, Qureshi A R, Bàràny P et al. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727-35.
24. van Guldner C, Janssen MJ, Lambert J, et al. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy. Perit Dial Int 1998; 18: 282-9.
25. Jennette JC, Goldman IC. Inhibition of the membrane transport of folate anions retained in uremia. J Lab Clin Med 1975; 86: 834-43.
26. Livant EJ, Tamura T, Johnston KE, et al. Plasma folate coniugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 1994; 5: 504-9.
27. Schemin D, Boston A G, Selhub J. Treatment of hyperhomocysteinemia in end stage renal disease. Am J Kidney Dis 2001; 38 (suppl 1): S91-4.
28. Suliman ME, Stenvinkel P, Bàràny P, et al. Hyperhomocysteinemia and its relationship with cardiovascular disease in ESRD: influence of hyperalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 2003; 41 (suppl): S89-95.
29. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentrations in hemodialysis patients. Am J Kidney Dis 1997; 29: 658-68.
30. Suliman ME, Stenvinkel P, Bàràny P, et al. Relationship between changes in plasma total homocysteine and serum albumin following renal replacement therapy. J Am Soc Nephrol 2002; 13: 760A.
31. Brulez HF, van Guldener C, Donker AC, et al. The impact of an amino-acid based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Trasplant 1999; 14: 154-9.
32. Kunz K, Petitjean P, Lisri M, et al. Cardiovascular morbidity and endothelial dysfunction in chronic hemodialysis patients. Miner Electrolyte Metab 1997; 23: 170-3.
33. van Guldener C, Lambert J, ter Wee PM, et al. Carotid artery stiffness in patients with end-stage renal disease: No effect on long-term homocysteine lowering therapy. Clin Nephrol 2000; 53: 33-41.
34. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 1998; 9: 533-9.
35. Ueland PM, Refsum H, Baresford SA, et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-32.
36. Graham I M, Daly LE, Refsum H, et al. Plasma homocysteine as a risk factor for cardiovascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
37. Widner B, Enzinger C, Laich A, et al. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab 2002; 3: 225-32.
38. Massy ZA. Potential strategy to normalize the levels of homocysteine in chronic renal failure patients. Kidney Int 2003; 63 (suppl): S134-6.
39. Righetti M, Ferrario G, Milani S. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patient. Med Sci Monit 2003; 9: P137-42.